Skip to main content
PMC home page
Orphanet Journal of Rare Diseases logoLink to Orphanet Journal of Rare Diseases
. 2024 Apr 1;19:142. doi: 10.1186/s13023-024-03110-3

Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A

Shahram Attarian 1,✉, Peter Young 2, Thomas H Brannagan 3, David Adams 4, Philip Van Damme 5,6, Florian P Thomas 7,8, Carlos Casanovas 9,10, Jafar Kafaie 8, Céline Tard 11, Maggie C Walter 12, Yann Péréon 13, David Walk 14, Amro Stino 15, Marianne de Visser 16, Camiel Verhamme 16, Anthony Amato 17, Gregory Carter 18, Laurent Magy 19, Jeffrey M Statland 20, Kevin Felice 21
PMCID: PMC10985943  PMID: 38561848

Correction to: Orphanet Journal of Rare Diseases (2021) 16:433

10.1186/s13023-021-02040-8

Following publication of the original article [1], we have been notified that we should add one more author to the authors’ group:

Jafar Kafaie 8

8 Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA

The original article was updated.

Footnotes

The online version of the original article can be found at 10.1186/s13023-021-02040-8

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Attarian, et al. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–tooth type 1A. 2021;16:433. 10.1186/s13023-021-02040-8. [DOI] [PMC free article] [PubMed]

Articles from Orphanet Journal of Rare Diseases are provided here courtesy of BMC

RESOURCES